Mangoceuticals announces the development of proprietary oral formulations of Semaglutide and Tirzepatide to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRx’s new oral formulations are poised to revolutionize the weight loss market and capture significant market share. “We are thrilled to introduce ‘Slim’ and ‘Trim’, MangoRx’s oral formulations of Semaglutide and Tirzepatide, to the weight loss market,” said Jacob Cohen, CEO and Co-Founder of MangoRx. “Our goal is to provide patients with a convenient and effective way to manage their weight and improve their overall health. We believe that these oral formulations have the potential to significantly impact the lives of millions of people worldwide.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
- Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
- Mangoceuticals granted 180-day extension to meet Nasdaq minimum bid price
- Mangoceuticals acquires a global patent portfolio for preventative care
- Mangoceuticals files to sell 30.01M shares of common stock for holders